NCI-H920細(xì)胞
年限： stage 4
數(shù)量： 大量
生長狀態(tài)： 懸浮生長
運(yùn)輸方式： 凍存運(yùn)輸
器官來源： 肺
是否是腫瘤細(xì)胞： 0
物種來源： 人
ATCC Number： CRL-5850?
相關(guān)**： 非小細(xì)胞肺癌
Designations: NCI-H920 [H920]
Depositors: AF Gazdar, JD Minna
NCI-H920細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage 4
Disease: adenocarcinoma; non-small cell lung cancer
Derived from metastatic site: lymph node
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: NCI-H920細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 11
D16S539: 11,13
D5S818: 13
D7S820: 10,11
THO1: 9.3
TPOX: 8,11
vWA: 19
Age: 43 years
Gender: male
Ethnicity: Caucasian
Comments: NCI-H920細(xì)胞The line was established in December 1984.
The patient received prior radiation therapy.
The patient was a smoker.
75 pack years.
Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)
The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
0.02 mg/ml insulin
0.01 mg/ml transferrin
25 nM sodium selenite (final conc.)
50 nM Hydrocortisone (final conc.)
1 ng/ml Epidermal Growth Factor (do not filter)
0.01 mM ethanolamine (final conc.)
0.01 mM phosphorylethanolamine NCI-H920細(xì)胞(final conc.)
100 pM triiodothyronine (final conc.)
0.5% (w/v) bovine serum albumin (final conc.)
0.5 mM sodium pyruvate (final conc.)
extra 2mM L-glutamine (for final conc. of 4.5mM)
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
